








































Werner Syndrome (WS) is an autosomal recessive 
disorder characterized by premature aging, elevated 
genomic instability and increased cancer [1]. Cells from 
WS patients have a reduced replicative life span [2]. 
WS cells exhibit genomic instability with DNA 
deletions, insertions, and rearrangements [3]. In 
addition, WS cells show hypersensitivity to some DNA 
damaging agents, including 4-nitroquinoline-1-oxide 
(4NQO) and topoisomerase inhibitors as well as mild 
sensitivity to ionizing radiation [4, 5]. The WRN protein 











































multimerization region, an acidic region, a helicase 
domain, a RecQ conserved (RQC) domain, a helicase 
and ribonuclease D/C-terminal (HRDC) domain and a 
nuclear localization signal (NLS) [6, 7]. 
 
WRN localizes to nucleoli under normal conditions, and 
translocates to the nucleoplasm in response to stress. It 
is proposed that post-translational modifications of 
WRN such as phosphorylation, acetylation, and 
sumoylation occur in response to stresses and affect its 
dynamics [8]. WRN is phosphorylated at serine, 
threonine or tyrosine residues by several kinases in 
response to DNA damage or stress. Tyrosine kinase, c- 
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Abl-mediated phosphorylation of WRN after bleomycin 
treatment or after replication stress has been correlated 
to WRN delocalization from nucleoli to DNA damage-
induced foci in the nucleoplasm [9]. WRN is also 
phosphorylated in an ATR/ATM dependent manner in 
response to DNA replication arrest or DNA damage 
during S phase of the cell cycle [10]. Suppression of 
ATR-mediated phosphorylation of WRN prevents 
proper accumulation of WRN in nuclear foci, causing 
breakage of stalled forks [10]. Inhibition of ATM-
mediated phosphorylation of WRN leads to retention of 
WRN nuclear foci, resulting in reduced viability after 
fork collapse[10]. Thus, phosphorylation of WRN by c-
Abl, ATR or ATM affects translocation of WRN. 
 
DNA-dependent kinase (DNA-PK) also targets WRN in 
vivo after treatment with regents that cause DNA double 
strand breaks (DSBs) [5, 11]. DSBs are cytotoxic 
lesions that can lead to mutation or cell death if not 
repaired proficiently. In mammalian cells, there are two 
major pathways for DSB repair: non-homologous end 
joining (NHEJ) and homologous recombination 
(HR)[12]. The DNA-PK complex, comprised of the 
DNA-PK catalytic subunit (DNA-PKcs) and the Ku 
70/86 heterodimer, is an essential factor for NHEJ in 
mammalian cells and telomere maintenance, together 
with the XRCC4/DNA ligase IV (X4L4) complex [13-
18]. Previous studies indicate that WRN interacts with 
NHEJ factors, and that its enzymatic activities are 
affected by the interaction. Ku 70/86 is one of the most 
prominent protein-interactors of WRN, and it promotes 
WRN exonuclease activity [19, 20]. The X4L4 complex 
binds to WRN and alters its exonuclease activity [21]. 
WRN also accumulates at laser-induced DSBs [22]. 
Together, these data suggest a role for WRN 
phosphorylation in the repair of DSBs. Ser-319 was 
identified as a singular and unique phosphorylation site 
by DNA-PK within WRN (1-333) [7]. The serine is 
located proximal to a WRN multimerization region, and 
the phosphorylation at this site affects neither 
exonuclease activity nor multimeric state [7]. 
Phosphorylation residues for DNA-PK in other regions 
of WRN in response to DSBs have not yet been 
identified. 
 
In this study, we asked whether WRN is phosphorylated 
by DNA-PK at other residues in response to DSBs, and 
whether the phosphorylation affects its translocation in 
cells. In comparison with wild type WRN, we analyzed 
the localization of phosphorylation mutants of WRN in 
response to DSBs produced by micro irradiation in the 
nucleus of human living cells. We also analyzed the 
sensitivity of WS cells overexpressing WRN 




DNA-PK phosphorylates WRN within the putative 
acidic repeats and in the C-terminus 
 
To map the region of WRN that is phosphorylated by 
DNA-PK, we first performed in vitro phosphorylation 
assays using a series of WRN fragments (Fig. 1). The 
WRN fragments are shown in Fig. 1A. These fragments 
were partially purified from E. coli using His- or GST-
tags, and incubated with purified DNA-PKcs and Ku 
70/80 in the presence of activated DNA and [γ-32P]ATP. 
The samples were subjected to SDS-PAGE and amido 
black staining, and the phosphorylation was visualized 
(Figs. 1B and 1C). GST itself was not phosphorylated by 
DNA-PK (Fig. 1C, lane 6). We found that the 
phosphorylation sites were located in the acidic region of 
WRN (239-499), and in the C-terminal domain of WRN 
(949-1432) (Fig. 1C, lanes 3 and 5). The signal from 
WRN (239-499) was much stronger than that of WRN 
(949-1432), suggesting that a major phosphorylation site 
or multiple phosphorylation sites are located in the acidic 
region. For fine mapping of WRN phosphorylation sites 
in the C-terminal domain, a truncated WRN (949-1236) 
was examined further, and since it was not phospho-
rylated, the minor phosphorylation site(s) were likely 





























Figure 1.   Mapping  DNA‐PK  phosphorylation  sites  in  WRN.  (A)  Schematic 
representation  of  His‐  or  GST‐tagged  WRN  fragments  used  in  in  vitro
phosphorylation assay. (B and C) In vitro phosphorylation assay. Purified His‐ or GST‐
tagged WRN  fragments  were  incubated  with  purified  DNA‐PKcs,  Ku  70/86,  and 
activated DNA in the presence of [γ‐32P]ATP. Amido black staining is shown (B). The 
phosphorylation was visualized  (C). Asterisk  indicates  the GST  (500‐946)  fragment. 
Note that GST (239‐499) migrated slower because of many acidic amino acids. 
  












































We also analyzed phosphorylated WRN by mass 
spectrometry and identified the amino acids. 
Recombinant full length WRN purified from Sf9 cells 
was phosphorylated in vitro by DNA-PK, and subjected 
to SDS-PAGE. Full length WRN was excised from the 
gel and subjected to in-gel trypsin digestion. The 
trypsinized samples were enriched for phospho-peptides 
using an immobilized metal affinity column (IMAC) 
and the enriched peptide mixtures were analyzed using 
LC-MS/MS. We obtained four peptides, 
STEHLSPNDNENDTSYVIESDEDCEME (421-447), 












































and/or 451-477), SLENLNSGTVEPTHSK (478-493) 
and AYSSSQPVISAQEQETQIVLYGK (1137-1159), 
containing serine as a phosphorylated candidate 
(underlined). Note that the HLSPNDNENDTSYVIESD 
LEMEMLK peptide may originate from 424-450 and/or 
451-477, because 424-477 consists of two tandem 
repeats of 27 amino acids. The results suggested that 
Ser-440, -467, -478 or -1141 might be phosphorylated 
in the in vitro phosphorylation assay. Ser-440 and -467 
are located in the acidic repeat, and Ser-478 is located 
just after the repeats (supplementary Fig. S2). This is 
consistent with the results from the in vitro 
 
 




tagged  full  length  WRN  (800  ng)  was  loaded  to  assign  the  position  of  endogenous  WRN  (lane  5).  The
phosphorylated proteins were  visualized  (upper panel),  followed by Western blotting with  anti‐WRN  antibody
(lower panel). (B) 293T cells transfected with pEGFP‐WRN were treated with 5 µg/ml bleomycin in the presence of
PI‐3 kinase  inhibitors, 25 µM wortmannin  (lane 2) and 20 µM NU7026  (lane 3).  (C) 293T cells  transfected with
pEGFP‐WRN  [wild  type  (WT)  or  mutant  as  indicated]  were  treated  with  or  without  5 µg/ml  bleomycin  as
indicated. Recombinant His‐tagged full length WRN was loaded (lane 7). (D) In vivo phosphorylation assays using
anti‐phosphoserine  antibody.  HEK293  cells  transfected  with  pEGFP‐WRN  (WT  or  mutant  as  indicated)  were
treated with (lanes 5‐8) or without 5 µg/ml bleomycin (lanes 1‐4),. EGFP proteins were immunoprecipitated with
anti‐GFP  antibody.  The  phosphorylated  proteins were  detected  by Western  blotting with  anti‐phosphoserine
antibody. The membrane was deprobed and analyzed by Western blotting with anti‐WRN antibody. 
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phosphorylation assay (Fig. 1C). Ser-1141 is also a 
candidate for phosphorylation based on the result of 
the LC-MS/MS analysis. However, WRN (949-1236) 
was not phosphorylated in vitro (supplementary Fig. 
S1). 
 
Ser-440 and -467 are phosphorylated in vivo by 
DNA-PK in response to bleomycin treatment 
 
To address whether phosphorylation at Ser-440, -467, -
478 or -1141 takes place in vivo, we performed an in 
vivo phosphorylation assay. 293T cells were transfected 
with a vector to overexpress N-terminally EGFP-tagged 
WRN and incubated in the presence of [32P] labeled 
orthophosphoric acid and bleomycin to introduce DSBs. 
Cells were then lysed and WRN was immuno-
precipitated. The products were subjected to SDS-
PAGE and transferred to a PVDF membrane. First, we 
tested whether exogenous WRN was phosphorylated in 
vivo in response to DSBs. To distinguish EGFP-WRN 
from endogenous WRN, we loaded recombinant full 
length His-tagged WRN, which migrated at almost the 
same position as endogenous WRN. However, 
endogenous WRN was not detected in this experiment 
(Fig. 2A, lanes 1, 2 and 5). EGFP-WRN was detected 
and was phosphorylated more in the presence of 
bleomycin than in its absence, suggesting that 
exogenous WRN is phosphorylated in response to 
bleomycin (Fig. 2A, compare lanes 3 and 4). Next, we 
tested whether bleomycin induced-phosphorylation was 
DNA-PK dependent. Cells overexpressing EGFP-WRN 
were treated with bleomycin in the presence of either 
the PI-3 kinase inhibitor wortmannin (IC50=5 µM for 
DNA-PK and ATM, IC50>100 µM for ATR) or the 
DNA-PK inhibitor NU7026 (Fig. 2B). In the presence 
of either of these inhibitors, EGFP-WRN was less 
phosphorylated in vivo, suggesting that the 
phosphorylation of exogenous WRN was at least 
partially DNA-PK-dependent (Figs. 2B). To determine 
which serine among 440 or 467, 478 and 1141 was 
phosphorylated by DNA-PK in vivo, we introduced Ala 
mutations to the pEGFP-WRN vector at those sites 
individually or in combination, and then performed in 
vivo phosphorylation assays (Figs. 2C and 2D). EGFP-
WRN S1141A was phosphorylated at almost the same 
level as the EGFP-WRN wild type, and so was EGFP-
WRN S478A, suggesting that Ser-478 and -1141 were 
not phosphorylated in vivo. EGFP-WRN S440A/S467A, 
EGFP-WRN S440/S467A/S478A, and EGFP-WRN 
S440/S467A/S478A/S1141A were barely phosphory-
lated, suggesting that either one or both Ser- 440 and -
467 were responsible for the phosphorylation. We 
detected a small amount of endogenous WRN or 
degraded EGFP-WRN, distinct from EGFP-WRN (Figs. 
2C). Next, we introduced a mutation at either of these 
two serines. HEK293 cells were transfected with these 
vectors, and incubated in the presence of bleomycin to 
introduce DSBs. Cells were then lysed and GFP-WRN 
was immunoprecipitated. The products were subjected 
to SDS-PAGE and transferred to a PVDF membrane. 
Phosphorylated WRN was detected using anti-
phosphoserine antibody (Fig. 2D). EGFP-WRN wild 
type, but not S440A, S467A and S440A/467A was 
phosphorylated in response to bleomycin (Fig. 2D). 
Based on these experiments, we concluded that WRN is 
phosphorylated at both Ser-440 and -467 by DNA-PK 
in response to bleomycin treatment in vivo. 
 
Ser-440 and -467 are phosphorylated in vitro by 
DNA-PK 
 
Experiments were then performed to confirm that Ser-
440 and -467 are phosphorylated in vitro. The GST-
WRN (239-499) fragment with alanine substitution at 
Ser-440 and/or -467 was expressed in bacterial cells and 
partially purified. The mutated WRN fragment was 
utilized in in vitro phosphorylation assays (Fig. 3). The 
products were subjected to SDS-PAGE and transferred 
to a PVDF membrane. The fragment without mutation, 
but not the one with S440A and S467A substitution was 
phosphorylated by DNA-PK (Fig.3, lanes 4 and 8). 
Consistent with results in Fig. 2D, neither S440A nor 
S467A single mutant was phosphorylated (Fig. 3, lanes 
6 and 10), suggesting that Ser-440 is required for 
phosphorylation of Ser-467 and that Ser-467 is required 
for phosphorylation of Ser-440. We also did not detect 
phosphorylation of the GST-WRN (239-499) fragment 
containing Ser-319, which is another residue 
phosphorylated by DNA-PK. The N-terminal region of 
WRN may be required for the phosphorylation, since 
WRN (1-333) was used for the Ser-319 phosphorylation 
experiments [7]. Taken together with the results from 
the in vivo phosphorylation assay, Ser-440 and -467 are 
major phosphorylation sites by DNA-PK both in in vitro 
and in vivo. 
 
The WRN phosphorylation at Ser-440 and -467 is 
not required for its accumulation at DSBs 
 
To understand the biological significance of WRN 
phosphorylation at Ser-440 and -467, we analyzed WRN 
translocation within the nucleus using laser 
microirradiation and confocal microscopy. WRN 
localizes in nucleoli under normal conditions, and leaves 
the nucleoli to form foci in response to various stresses. 
Previously Lan et al. reported that GFP-WRN 
accumulated at sites of DSBs and the fluorescence at the 
sites reached a plateau within 3 min [22]. To set up 
conditions to produce DSBs by laser irradiation, we 
irradiated HeLa cells with the laser at several doses, and 
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immunostained for γH2AX. We observed γH2AX foci at 
the site of irradiation using 14% intensity with a 435 nM 
laser (data not shown). HeLa cells were transfected with 
vectors to overexpress EGFP-WRN wild type, S440A, 
S467A or S440A/S467A mutants, and microirradiated at 
14% intensity with the 435 nM laser to induce DSBs. 
EGFP-WRN wild type localized at nucleoli before 
irradiation, and accumulated at the sites of irradiation in a 
time-dependent manner. Within a second after irradiation 
WRN accumulated at the irradiated sites and fluores-












































irradiation (Fig. 4, upper panels). All of the 
phosphorylation mutants, EGFP-WRN S440A, S467 and 
S440A/S467A, also localized at nucleoli before 
irradiation, and accumulated at the irradiated site with the 
same kinetics as wild type. We confirmed that 
accumulation kinetics of the EGFP- WRN wild type and 
S467A was similar by quantifying and plotting of the 
fluorescence signals up to 60 seconds (supplementary 
Fig. S3). These results indicated that phosphorylation of 
WRN by DNA-PK is not required for its accumulation at 













































Figure  3. In  vitro phosphorylation  at  Ser‐440  and  ‐467  by








S467A  or  S440A/S467A)  were  laser‐irradiated  at  the  sites  indicated  by  arrows.  Time‐
dependent accumulation of EGFP‐WRN WT and mutants at the DSBs sites were shown. 
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Ser-440 and -467 are required for WRN 
relocalization to nucleoli 
 
After the intensity of fluorescence of EGFP-WRN 
reached a plateau in the irradiated sites, it persisted at 
least for 4 hours after the laser irradiation[22]. 
Consistent with this, EGFP-WRN wild type and 
mutants persisted at the site of DSBs up to 1 hour in 
HeLa cells (data not shown). To address whether 
phosphorylation of WRN by DNA-PK affects its 
retention at the foci, we analyzed the accumulation of 
exogenous EGFP-WRN or the phosphorylation 
mutants in WS cells after 24 hours-recovery from 
exposure to etoposide, a DNA topoisomerase II 
inhibitor, which produces DSBs irrespective of DNA 
replication (Fig. 5A). All of the phosphorylation 






































without etoposide exposure (Fig. 5A, undamaged). 
Consistent with a previous report [23], the wild type, 
as well as S440A, S467A, and S440A/S467Amutants 
formed foci in the nucleoplasm upon exposure to 
etoposide (Fig. 5A, 0 h). After the recovery, wild type 
WRN relocated to nucleoli, whereas many more foci 
of the phosphorylation mutants of WRN remained in 
the nucleoplasm (Fig. 5A, 24 h). The percentage of 
cells showing EGFP-WRN wild type foci in the 
nucleoplasm decreased to 20% after 24 hours-recovery 
from etoposide-induced damage, whereas for S440A 
66% cells, for S467A 75% cells and for S440A/S467A 
73% cells showed foci at the nucleoplasm after the 
recovery (Fig. 5B). These data suggested that the 
major phosphorylation sites, Ser-440 and -467, are 








































Figure 5. WRN  but  not  phosphorylation mutant  relocalizes  to  the  nucleoli
post etoposide exposure.  (A) AG11395  cells overexpressing either EGFP‐WRN wild
type  (WT)  or  mutant  (S440A,  S467A  or  S440A/S467A)  were  incubated  with  35  μM
etposide for 3 hours. Cells were fixed and EGFP signals were visualized before and after
incubation  for another 24 hours  in  fresh medium. Representive  images are shown.  (B)
The percent of cells containing WRN  foci. At  least 100 cells were scored at each  time







































Phosphorylation of Ser-440 and -467 leads to 
decreased cellular sensitivity to etoposide 
 
To test whether retained WRN phosphorylation mutant 
foci represent non-repaired DSBs, we performed 
alkaline comet assays. WS cells expressing EGFP-
WRN wild type or mutants were treated with 35 μM 
etoposide for 3 hours, were allowed to recover for 24 
hours, and were assayed. As expected, DSBs were 
decreased in cells expressing either type of WRN after 
recovery for 24 hours (Fig. 6A and B, compare 0 h and 
24 h). However, there was an increase in residual DSBs 
in cells overexpressing either of the WRN mutants after 
24 hour-recovery. We also examined cytotoxicity by 
etoposide by evaluating cell proliferation by the MTT 
assay (Fig. 6C). Cells were treated with 15-35 μM 
etoposide for 3 hours, and were allowed to recover for 
24 hours. WRN wild type overexpressing WS cells 
exhibited a significant decrease in sensitivity to 
etoposide toxicity, compared to WS cells transfected 
with empty vector. WS cells expressing either of 


































sensitivity, compared to the one transfected with empty 
vector. These results suggested that phosphorylation of 
WRN contributes to the protection of cells from DSBs 




We have identified Ser-440 and -467 of WRN as DNA-
PK phosphorylation sites both in vitro and in vivo using 
bleomycin to produce DSBs. WRN has putative acidic 
repeats in 424-477, and Ser-440 and -467 are located in 
the first and second acidic repeat, respectively. We 
overexpressed WRN mutants with substitution of Ser-
440 and/or -467 to Ala, examined the response to laser-
induced DSBs in live HeLa cells, and found similar 
accumulation of all mutants to at DSBs as wild type. 
Also, the accumulated mutants as well as wild type 
WRN resided up to an hour after irradiation (data not 
shown). This is consistent with a report suggesting that 
the HRDC (helicase and RNaseD C-terminal) domain 
(1021-1432) was necessary and sufficient for the 
accumulation to DSBs [22]. We examined the WRN 
Figure  6.    Cells  overexpressing  the  phosphorylation  mutants  are  moderately
sensitive to etoposide. (A) Comet assay with AG11395 cells overexpressing either EGFP‐WRN
wild  type  (WT)  or  mutant  (S440A,  S467A  or  S440A/S467A)  24  h  after  35  μM  etoposide
treatment. Representive images are shown. (B) Tail length in (A) are indicated. At least 17 cells
were measured. Asterisks (*) indicate significant difference between 0 h and 24 h (p<0.05). Plus
(+)  indicate  significant  difference  between  Wild  type  and  mutants.  (C)  AG11395  cells
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localization after 24 hour-recovery from etoposide-
induced DNA damage in WS cells. Interestingly, WRN 
wild type translocated back to nucleoli, whereas the 
phosphorylation mutants persisted as nucleoplasmic 
foci, suggesting that Ser-440 and -467 contribute to the 
relocalization of WRN to nucleoli. We found that more 
DSBs persisted in WS cells expressing WRN mutants 
compared to wild type after 24 hour-recovery from 
etoposide exposure. Inhibition of proliferation of these 
cells by etoposide was also tested by the MTT assay. In 
our experiments, the WS cells expressing EGFP-WRN 
showed decreased sensitivity to etoposide, compared to 
those transfected with empty vector (Fig. 6), consistent 
with a previous report[24], though inconsistent results 
have been reported about sensitivity of WS cells to 
etoposide. In another study, they utilized WRN 
knockdown osteosarcoma cells and 50 % of cells died 
after exposure to 10 µM of etoposide[25]. In our case, 
we utilized WRN deficient fibroblast, where no wild 
type WRN protein exists, and much higher 
concentrations of etoposide were used (up to 40 μM). A 
small amount of WRN may be enough to repair 
etoposide-induced DSBs. Additionally DSBs produced 
by such higher concentration of etoposide are repairable 
as we observed in our comet assay (Fig.6). Based on 
current and previous data, we hypothesize a model for 
WRN at DSBs. Once DSBs are formed, the HRDC 
domain of WRN may either bind to the DSBs or interact 
with other proteins present at DSBs. WRN recruitment 
is not dependent on Ku, which binds to DSBs at an 
early step during NHEJ and has strong affinity to 
WRN[22]. When both DNA-PK and WRN are at the 
sites of DSBs, WRN Ser-440 and/or -467 are 
phosphorylated by the kinase. The phosphorylation of 
WRN may regulate its catalytic activities [11], and may 
also help recruit other proteins for proficient repair. 
Thus, fine tuning between DSB repair and regulation of 
catalytic activities of WRN is essential for DNA repair 
explaining the genomic instability observed in WS 
patients. How this regulation contributes to in vivo 
DNA repair remains speculative but we have clearly 
found specific target sites of DNA-PK on WRN. It 
seems likely from our observations that restoration of 
WRN to nucleoli indicates completion of DNA repair. It 
is evident from many previous studies that WRN 
relocation from nucleoli to the nucleoplasm represents 
an important aspect of the cellular role of WRN [8, 26]. 
 
WRN is a member of the RecQ DNA helicase family, 
which includes BLM, RECQL4, RECQ1, and RECQ5 
[27, 28]. RecQ helicases contribute to genome stability 
by regulating HR through various mechanisms [29]. 
BLM, in particular, has common functions with WRN, 
and is also phosphorylated on multiple residues by 
different kinases either after stress induction or during 
mitosis. WRN Thr-99 and -122 are phosphorylated by 
replicative stress induced by hydroxyurea [30]. Ser-646 
is constitutively phosphorylated by Chk1, and treatment 
of cells with DNA damaging agents leads to decrease of 
the phosphorylation and relocalization of BLM to the 
site of DNA damage [31]. Ser-714 and Thr-766 are also 
phosphorylated by cdc2 in mitosis [32]. In contrast to 
Ser-440 and -467 in the acidic region in WRN, neither 
of these serines and threonines is located in the acidic 
region in BLM. Thus, phosphorylation of the acidic 
region may be unique to WRN. Because 
phosphorylation of WRN by DNA-PK regulates its 
exonuclease and helicase activities [11], WRN 
phosphorylation may influence the dissociation of HR 
intermediates. 
 
DNA-PKcs belongs to the PI-3 kinase family with 
ATR, ATM and other kinases, and WRN is also a 
substrate for ATR and ATM kinases in response to 
replication blockage [33, 34], raising the possibility that 
Ser-440 and -467 are also phosphorylated by ATR or 
ATM. The major phosphorylation sites by ATR are Ser-
991, Thr-1152 and Ser-1256 [10]. Ser-1141, -1058 and -
1292 were previously identified as phosphorylation sites 
by ATM[33]. Thus, Ser-440 and -467 have not been 
identified as substrates so far. In addition, the minimal 
consensus sequence of ATR or ATM is the SQ/TQ 
motif, and Ser-440 and -467 are followed by D. 
Therefore, these two serines may not be targets of ATR 
and ATM. Taken together, Ser-467, the major DNA-PK 
phosphorylation site is unlikely to overlap with the ATR 
and ATM phosphorylation sites. LC-MS/MS analysis 
detected phosphorylation at Ser-1141, however, results 
from in vitro phosphorylation excluded the serine as a 
substrate for DNA-PK. ATM may have already 
phosphorylated the WRN protein in Sf9 cells before or 
during protein purification, resulting in detection of 
background phosphorylation. ATR and ATM promote 
recovery from perturbed replication by differently 
regulating WRN at defined moments of the response to 
replication fork arrest [10]. Thus, these three PI-3 
kinases respond to incidents on DNA through 
phosphorylation of WRN at different positions and at 
different times. 
 
MATERIALS AND METHODS 
 
Cells. HEK293 cells, 293T cells and HeLa cells were 
grown in monolayer in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine 
serum, 50 µg/ml streptomycin and 50 U/ml penicillin. 
SV40-transformed Werner (AG11395) cells were 
grown in monolayer in minimum essential medium 
(MEM) supplemented with 10% fetal bovine serum, 50 
µg/ml streptomycin and 50 U/ml penicillin, 1% amino 
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acids, 1% vitamins and 2 mM L-glutamine (Life 
Technologies, Carlsbad, CA, USA). 
 
Proteins. The GST-WRN fragments were overexpressed 
in Escherichia coli BL21(DE3) pLysS and purified as 
previously described [35, 36]. His-tagged full length 
WRN [37], His-tagged WRN fragment (1-368)[37], 
untagged, human Ku 70/86 [38] and DNA-PKcs[39] 
were purified using a baculovirus expression system as 
described previously. 
 
Vectors. Site-directed mutagenesis was performed on 
pEGFP-WRN[40] in order to change amino acid 
residues of WRN, Ser-440, -467, --478 and -1141, to 
alanine using the QuikChange II Site-Directed 
Mutagenesis Kit or the QuikChange Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, 
CA, USA). Mutations were confirmed by sequencing. 
 
In vitro phosphorylation. 7.5 µM WRN fragment and 
0.2 µM Ku 70/86 in 10 µl of kinase buffer [50 mM 
KCl, 1 mM dithiothreitol, 25 mM Hepes-KOH (pH 
7.5), 5 mM MgCl2, 250 µM ATP, 1 µCi of [γ-32P]ATP, 
and 100 ng of sonicated calf thymus DNA] were 
incubated with 0.05 µM DNA-PKcs at 30°C for 
15 min. The reactions were stopped by the addition of 
1% SDS. The resulting products were analyzed by 4-
15% SDS-PAGE. The proteins on the gel were 
transferred to a PVDF membrane. The membrane was 
analyzed on a Typhoon Phophorimager (GE 
Healthcare, Piscataway, NJ, USA) and quantified 
using Imagequant software (GE Healthcare), followed 
by amido black staining. 
 
In vivo phosphorylation. Phosphorylated WRN was 
detected by radio-labeling as previously reported11 or by 
probing with anti-phosphoserine antibody. Briefly, 
293T cells were transfected with pEGFP-WRN vector 
using Polyfect Transfection Reagent (Qiagen, Valencia, 
CA, USA), and were incubated with phosphate-free 
DMEM (Life Technologies) for 1 hour to exhaust the 
pool of endogenous phosphate. The cells were then 
incubated with phosphate-free medium containing 
100 µCi of [32P] orthophosphate (GE healthcare) and 
5 µg/ml bleomycin (Sigma-Aldrich, St Louis, MO, 
USA) for 5 hours. In some experiments, 25 µM 
wortmannin (Sigma-Aldrich) or 20 µM NU7026 was 
added during the incubation period. The cells were then 
lysed with RIPA buffer A [150 mM NaCl, 1% Triton, 
0.1% SDS, 10 mM Tris (pH 8.0), 0.5% sodium 
deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride, 
20 µg/ml aprotinin, 10 µg/ml leupeptine, 1 mM sodium 
orthovanadate and 10 units/ml DNase I (New England 
Biolabs, Beverly, MA, USA)] supplemented with 
phosphatase inhibitors (1:1,000, Sigma-Aldrich). After 
centrifugation, the supernatant was precleared with 
Recombinant Protein G Agarose (Life Technologies) 
and incubated with 4 µg of polyclonal rabbit anti-WRN 
antibody (sc-5629, Santa Cruz Biotechnology, Dallas, 
TX, USA) for 16 hours. The immuno complexes were 
collected by adding Recombinant Protein G agarose and 
washed three times with RIPA buffer A. 
Immunoprecipitated proteins were eluted with SDS and 
analyzed by 4-15% SDS-PAGE. The proteins were 
transferred to a PVDF membrane and analyzed on a 
Typhoon Phophorimager using ImageQuant TL 
software (GE Healthcare). Western blot was performed 
using mouse monoclonal anti-WRN antibody (BD 
Biosciences, San Jose, CA, USA). 
 
HEK293 cells were transfected with pEGFP-WRN 
vector using FuGENE 6 (Promega, Madison, WI, 
USA), and were incubated with 5 µg/ml bleomycin 
(Sigma-Aldrich) for 5 hours. The cells were then lysed 
with RIPA buffer B [150 mM NaCl, 0.05% NP-40 and 
50 mM Tris (pH 7.5)] supplemented with protease 
inhibitor cocktail without EDTA (Roche, Basel, 
Schweiz), and phosphatase inhibitors I (Sigma-
Aldrich). After centrifugation, the supernatant was 
incubated with 50 µl of anti-GFP magnetic beads 
(D153-9, MBL, Nagoya, Japan) for an hour. The 
complexes were washed three times with RIPA buffer 
B. Immunoprecipitated proteins were eluted with SDS 
and analyzed by 4-15% SDS-PAGE. The proteins were 
transferred to a PVDF membrane. Western blot was 
performed using mouse monoclonal anti-WRN 
antibody (BD Biosciences) or mouse anti-
phosphoserine antibody (ab-6639, Abcam, Cambridge, 
MA, USA). 
 
Identification of phosphorylation sites. In vitro 
phosphorylated WRN were separated by 4–15% SDS–
PAGE. The gel was then stained with Coomassie 
brilliant blue, and the band was then excised and 
subjected to in-gel tryptic digestion (Thermo Scientific, 
Waltham, MA, USA) according to the manufacturer's 
instructions. To identify the Ser/Thr phosphorylation 
site of WRN, the digests was subjected to immobilized 
metal affinity chromatography (IMAC) and analyzed by 
capillary-LC-MS/MS. 
 
Laser microirradiation and confocal microscopy. We 
employed a Nikon Eclipse TE2000-E (Nikon, Tokyo, 
Japan) with a Yokogawa CSU 10 Spinning Disk head 
(Yokogawa, Tokyo, Japan) for confocal microscopy. 
The set-up integrated a Stanford Research Systems 
NL100 nitrogen laser (Sunnyvale, CA, USA) by 
Micropoint ablation system (Photonic Instruments, St 
Charles, IL, USA). HeLa cells were grown on 35 mm 
glass bottom culture dishes (MatTek corporation, 
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Ashland, MA, USA) and 24 hours before targeting, 
transfected with pEGFP-WRN vector using 
Lipofectamine 2000 (Life Technologies). The power of 
the laser is attenuated through Improvison’s Volocity 
software 5.1 (PerkinElmer, Waltham, MA, USA) in 
terms of percent intensity. Positions internal to the 
nuclei of cells were targeted via a 40× oil objective lens. 
14% laser intensities were used to produce DSBs. 
Images were captured and analyzed using Volocity 
software (PerkinElmer).  
 
Detection of WRN foci after etoposide exposure. 
AG11395 cells were transfected with pEGFP-WRN 
vector using FuGENE HD (Promega). After 48 hours, 
cells were incubated with 35 μM of etoposide (Sigma-
Aldrich) for 3 hours and allowed to recover for 24 
hours, followed by fixation with 4% paraformaldehyde. 
EGFP-WRN foci were detected using a Leica DMLB 
100S microscope under 100× magnification. 
 
Comet assay. The alkaline single-cell gel electro-
phoresis assay (comet assay) was performed to detect 
DSBs as previously reported with minor modifications 
[41, 42]. Briefly, cells transfected with WRN expressing 
vector were treated with etoposide for 3 h. Cells were 
mounted in agarose gel on slides. The slides were 
incubated in lysis solution [2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris (pH 10), 10% DMSO and 1% 
Triton X-100] for 1 h at 4 °C. After washing with 0.4 M 
Tris (pH 7.5) for 20 min, the slides were 
electrophoresed in buffer [0.3 M NaOH and 1 mM 
EDTA] at 25 V (0.78 V/cm) for 20 min, and were 
stained with ethidium bromide (20 μg/ml). Nuclei were 
randomly chosen and were analyzed under fluorescence 
microscope (Leica Microsystems, Wetzlar, Germany). 
The percentages of tail DNA were evaluated using 
Komet Assay software (Komet version 5.5, Kinetic 
Imaging Ltd., Nottingham, United Kingdom) under 
400× magnification. 
 
Cell proliferation assay. AG11395 cells were seeded at 
a density of 2 × 105 cells per well in 24-well plates and 
incubated overnight. Cells were transfected with 
pEGFP-WRN vector using FuGENE HD. After 24 
hours of transfection, cells were exposed to 0, 15, 25 or 
35 µM etoposide for 3 hours and incubated for another 
24 hours in fresh medium. The cell proliferation was 
evaluated with standard (3, 4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay[43]. 
 
Statistical analysis. All statistical analyses were 
performed using Microsoft excel analysis tools. The 
data analysis was conducted using paired t test. The 
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